Prognostic role of progesterone receptor expression in a population-based analysis

Caldarella, Adele; Barchielli, Alessandro
December 2017
Journal of Cancer Research & Clinical Oncology;Dec2017, Vol. 143 Issue 12, p2505
Academic Journal
Purpose: The role of progesterone (PR) expression in the management of breast cancer is controversial. The aim of this study is to evaluate the characteristics and prognosis of progesterone status among breast cancers patients in a population-based analysis. Materials and methods: Through the Tuscan Cancer Registry data on all the invasive breast cancer cases diagnosed during the period 2004-2005 in the provinces of Florence and Prato, central Italy, were retrieved. Histological reports were re-examined to obtain information on the percentage of positive tumor cells for estrogen (ER), progesterone (PR) receptors, Ki67 marker and human epidermal growth factor 2 (HER2). Information on age, stage, differentiation grade were also obtained. Results: Out of 1487 patients, 28% had PR− breast cancer. These patients were older (p 0.006) than PR+ cancer patients, with more frequently high Ki67 ( p < 0.0001), HER2 + ( p < 0.0001), ER− ( p < 0.0001) tumoral expression. The ER+/PR+ subtype was the most represented (n.1053), while ER−/PR+ was the most rare (n.23); 210 cases (14.1%) ER+ PR− and 201 (13.5%) ER−/PR− cases were found. Analysis of survival by the Cox proportional hazards model showed an independent prognostic value of PR expression ( p < 0.0001), also when estrogen, Ki67, HER2 status and age were included. The 5-year cancer-specific survival was 82.1, 86.5, 100, 92% for ER−/PR−, ER+/PR−, ER−/PR+, ER+/PR+ subtype, respectively. Conclusions: Our study revealed significant differences in clinicopathological characteristics among breast cancer according to PR expression and confirmed its prognostic independent role, suggesting a role of PR in the improvement of breast cancer prognostic characterization.


Related Articles

  • Estrogen and Progesterone Receptor Status in Primary Breast Cancer -- A Study of 11,273 Patients from the Year 1990 to 2002. Vrbanec, Damir; Petričević, Branka // Collegium Antropologicum;Jun2007, Vol. 31 Issue 2, p535 

    The aim of this study was to gain insight of the breast cancer hormone receptor status of our patients, its stratification according to age as well as its changes during the period of 13 years. 11,273 patients with primary breast cancer from several towns in Croatia were included in this study....

  • Effect of Delayed Formalin Fixation on Estrogen and Progesterone Receptors in Breast Cancer. Jingxin Qiu; Kulkarni, Swati; Chandrasekhar, Rameela; Rees, Mark; Hyde, Kathryn; Wilding, Gregory; Dongfeng Tan; Khoury, Thaer // American Journal of Clinical Pathology;Nov2010, Vol. 134 Issue 5, p813 

    We previously reported that delayed formalin fixation (DFF) has a negative effect on immunohistochemical staining of estrogen receptor (ER), progesterone receptor (PR), and HER2. The primary aim of the study was to determine if DFF affected commonly used clones of the ER and PR differentially....

  • Hormonal Receptors Evaluation in Breast Cancer. Kamani, Fereshteh; Fathi, Afshin // Journal of Isfahan Medical School;7/18/2011, Vol. 29 Issue 139, p1 

    Background: Breast cancer is the most common site-specific cancer in women and is of the major leading causes of death from cancer for women aged 20 to 59 years. This study aimed to demonstrate certain biological, clinical and pathological characteristics and to evaluate the breast receptors of...

  • Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. Yust-Katz, S.; Garciarena, P.; Liu, D.; Yuan, Y.; Ibrahim, N.; Yerushalmi, R.; Penas-Prado, M.; Groves, M. // Journal of Neuro-Oncology;Sep2013, Vol. 114 Issue 2, p229 

    Leptomeningeal disease (LMD) occurs in 5 % of breast cancer patients. The aim of this study was to identify risk factors related to survival and time to development of LMD in breast cancer patients. A retrospective analysis of breast cancer patients with LMD, evaluated in MDACC between 1995 and...

  • Variable Specimen Handling Affects Hormone Receptor Test Results in Women With Breast Cancer. Nkoy, Flory L.; Hammond, M. Elizabeth H.; Rees, William; Belnap, Tom; Rowley, Braden; Catmull, Steve; Sause, William // Archives of Pathology & Laboratory Medicine;Apr2010, Vol. 134 Issue 4, p606 

    Context.—Intermountain Healthcare hospitals use a single, standardized laboratory and automated testing process for estrogen receptor/progesterone receptor (ER/PR) tests to minimize testing errors. Objectives.—To test the (1) variability in ER/PR negativity among hospitals and (2)...

  • Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. Faheem, Mohammad; Mahmood, Humera; Khurram, Mohammad; Qasim, Uzma; Irfan, Javaid // Ecancermedicalscience;2012, Vol. 6 Issue 271-285, p1 

    Objectives: To measure the frequency of estrogen receptor (ER), progesterone receptor (PR), and Her 2 Neu positivity and to study their association with tumour characteristics and menopausal status in a breast cancer cohort from Northern Pakistan. Methodology: Patients attending NORI with...

  • Oral Contraceptive Use and Estrogen Receptor-Negative Breast Cancer. Aksoy, Sercan; Dizdar, Omer; Altundag, Kadri // American Surgeon;Feb2011, Vol. 77 Issue 2, pE33 

    The article discusses research which was conducted to investigate characteristics of triple-negative breast cancers and compare them with nontriple-negative breast tumors in a Turkish population. Researchers evaluated 160 breast cancer patients. They found that 10.6% of subjects had...

  • ASCO and CAP aim to improve hormone-receptor testing for breast-cancer patients.  // MLO: Medical Laboratory Observer;Jun2010, Vol. 42 Issue 6, p34 

    The article reports on the guidelines issued by the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) whose basic motive is improving hormone receptor testing for breast cancer patients. Guidelines include testing estrogen(ER) and progesterone(PgR) receptors...

  • The role of estrogen receptors isoforms in breast cancer. Mandušić, Vesna; Nikolić-Vukosavljević, Dragica; Nešković-Konstantinović, Zora; Tanić, Nikola; Čeleketić, Dušica; Dimitrijević, Bogomir // Archive of Oncology;2006, Vol. 14 Issue 3-4, p106 

    Background: Estrogen and progesterone receptor (ER/PR) status is an accepted predictive marker in breast cancer. It is well known that breast tumors, which are ER(+) are more likely to respond to endocrine therapy. However, certain percentage of ER(+)/PR(+) tumors do not respond to endocrine...

  • Porcentaje de adiposidad y su relación con el índice de inmunorreactividad de los receptores hormonales en mujeres mexicanas con cáncer de mama. Balderas-Peña, Luz-M.a-Adriana; Sat-Muñoz, Daniel; Castro Cervantes, Juan Manuel; Ramírez-Orozco, Ricardo-Ernesto; Ángeles-Bueno, Wenceslao-Guillermo; Flores-Márquez, María-Rosa; Macías-López, Griselda-Guadalupe; Ruiz-Quezada, Sandra-Luz; Salcedo-Rocha, Ana-Leticia; García de Alba-García, Javier-Eduardo; Solano-Murillo, Pedro // Nutricion Hospitalaria;jul/ago2013, Vol. 28 Issue 4, p1321 

    Introduction: Adipose tissue is an important estrogen resource and they are involved in breast cancer development. Objective: To establish the relationship between adiposity percentage and the estrogen and progesterone receptors immunoreactive score in Mexican women with breast cancer. Methods:...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics